Evidence map›Paper›PMID 39989739›Full record

ArticlePeerJ2025

A novel microbial agent reduces soil paclobutrazol residue, enhances enzyme activities and increases

Xiaojun Jiang, Huadong Wang, Yi Huang, Hong Jin, Jianguo Ding, Lin Ma, Lei Zheng

Abstract read
In one paragraph

Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Metabolism of oxyfluorfen by actinobacteriaFrontiers in microbiology · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiaojun JiangSchool of Pharmacy, Sichuan College of Traditional Chinese Medicine, Mianyang, Sichuan, China.
Huadong WangSchool of Pharmacy, Sichuan College of Traditional Chinese Medicine, Mianyang, Sichuan, China.
Yi HuangCollege of Life Science and Engineering, Southwest University of Science and Technology, Mianyang, Sichuan, China.
Hong JinSchool of Pharmacy, Sichuan College of Traditional Chinese Medicine, Mianyang, Sichuan, China.
Jianguo DingMianyang Xintengyuan Traditional Chinese Medicine Co., Ltd., Mianyang, Sichuan, China.
Lin MaCollege of Life Science and Engineering, Southwest University of Science and Technology, Mianyang, Sichuan, China.
Lei ZhengSchool of Pharmacy, Sichuan College of Traditional Chinese Medicine, Mianyang, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Methods: Based on a novel microbial agent, Results: MYSH significantly reduced soil paclobutrazol residue by 75.18% over five months, compared to a natural degradation rate of 50.72% over a year. Compared to the control group, the MYSH-treated group enhanced soil sucrase activity, soil urease activity, and soil alkaline phosphatase activity, with rates of 47.81%, 46.70%, and 216.66%, respectively. Additionally, MYSH improved Conclusions: This study demonstrates the dual role of MYSH as both an environmental remediation agent and a crop productivity enhancer for the first time. By reducing paclobutrazol residue and enhancing soil health and crop production, MYSH shows great potential for broader application in sustainable agricultural practices. This research highlights the efficacy of microbial agents in addressing agrochemical contamination and promoting sustainable farming, providing a valuable contribution to the development of eco-friendly agricultural solutions.

Indexed as

MicrococcaceaeOphiopogonPesticide ResiduesSoilSoil MicrobiologySoil PollutantsTriazolesUreasepaclobutrazolPesticide ResiduesSoilSoil PollutantsTriazolesUreaseDry matter ratioEnzyme activityMicrobial agentOphiopogon japonicusPaclobutrazol residueYield

Identifiers

PMID39989739
PMCPMC11847490

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.